High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
639.49M
+6.4%
0.275
+129.5%
684.56M
+4.85%
0.337
+40.31%
651.89M
+5.67%
0.276
+14.83%
Estimates Revision
The market is revising Upward the revenue expectations for Envista Holdings Corporation (NVST) for FY2025, with the revenue forecasts being adjusted by 0.33% over the past three months. During the same period, the stock price has changed by 22.75%.
Revenue Estimates for FY2025
Revise Upward
+0.33%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.5%
In Past 3 Month
Stock Price
Go Up
+22.75%
In Past 3 Month
11 Analyst Rating
0Wall Street analysts forecast NVST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVST is 19.31 USD with a low forecast of 15.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
1 Sell
Moderate Buy
0Current: 20.830
Low
15.00
Averages
19.31
High
24.00
0Current: 20.830
Low
15.00
Averages
19.31
High
24.00
UBS
Kevin Caliendo
Neutral
maintain
$18 -> $22
2025-07-29
New
Reason
UBS
Kevin Caliendo
Price Target
$18 -> $22
2025-07-29
New
maintain
Neutral
Reason
UBS analyst Kevin Caliendo raised the firm's price target on Envista to $22 from $18 and keeps a Neutral rating on the shares.
Leerink
Market Perform
maintain
2025-07-14
Reason
Leerink
Price Target
2025-07-14
maintain
Market Perform
Reason
Leerink raised the firm's price target on Envista to $21.50 from $18.50 and keeps a Market Perform rating on the shares. Heading into Q2 earnings, the firm is updating dental company estimates and publishing the results of its fourth semi-annual dental survey of 63 dental practitioners in the United States. There is clearly a budding interest in identifying incremental improvements across the dental space, even if each opportunity seems to be company-specific in what remains a still-challenged total dental end-market, Leerink says. The firm sees reasons to be positive on each stock in its coverage but also has some offsetting questions that limit too much constructiveness.
Baird
Jeff Johnson
Neutral -> Outperform
upgrade
$21 -> $23
2025-05-27
Reason
Baird
Jeff Johnson
Price Target
$21 -> $23
2025-05-27
upgrade
Neutral -> Outperform
Reason
Baird analyst Jeff Johnson upgraded Envista to Outperform from Neutral with a price target of $23, up from $21. Baird's May domestic dental survey notably improved following bad April findings, the analyst tells investors in a research note. The firm says its feedback consistently points to stable to slightly improved dental demand last couple months, including in the U.S., but not to extent of the sequential inflection seen in this month's survey. It sees revenue and earnings upside for Envista in 2025 and 2026. Stable end markets and the recent China tariff relief will likely help this upside become increasingly apparent over the next couple quarters, contends Baird.
Mizuho
Underperform
downgrade
$18 -> $15
2025-04-24
Reason
Mizuho
Price Target
$18 -> $15
2025-04-24
downgrade
Underperform
Reason
Mizuho lowered the firm's price target on Envista to $15 from $18 and keeps an Underperform rating on the shares. The firm believes many companies in the dental sector "may post less-than-stellar growth" in Q1. The recent American Dental Association Q1 survey results further reinforce a cautious view, so Mizuho trimmed Q1 estimates for broad dental manufacturers, the analyst tells investors in a research note.
UBS
Kevin Caliendo
Hold
Maintains
$23 → $21
2025-03-10
Reason
UBS
Kevin Caliendo
Price Target
$23 → $21
2025-03-10
Maintains
Hold
Reason
UBS lowered the firm's price target on Envista to $21 from $23 and keeps a Neutral rating on the shares following the capital markets day. The company's 3-5 year mid-term framework of 2-4% core sales growth, 4%-7% adjusted EBITDA growth, and 7%-10% adjusted earnings growth appeared to "err on the side of conservatism" and was set under the assumption that the underlying dental market does not return to the historical levels of 3%-5% annual growth over the timeframe, the analyst tells investors in a research note. UBS believes Envista's targets are "achievable and rational" given the current environment, and that the stock should work when the macro environment improves.
Needham
David Saxon
Hold
Reiterates
n/a
2025-03-06
Reason
Needham
David Saxon
Price Target
n/a
2025-03-06
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Envista Holdings Corp (NVST.N) is 17.66, compared to its 5-year average forward P/E of 20.66. For a more detailed relative valuation and DCF analysis to assess Envista Holdings Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
20.66
Current PE
17.66
Overvalued PE
24.73
Undervalued PE
16.59
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
13.27
Current EV/EBITDA
10.43
Overvalued EV/EBITDA
15.51
Undervalued EV/EBITDA
11.02
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
1.95
Current PS
1.30
Overvalued PS
2.49
Undervalued PS
1.40
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
NVST News & Events
Events Timeline
(ET)
2025-07-31
16:28:18
Envista raises 2025 adusted EPS view to $1.05-$1.15 from 95c-$1.05
2025-07-31
16:24:50
Envista reports Q2 adjusted EPS 50c, consensus 23c
2025-05-15 (ET)
2025-05-15
11:26:32
Envista, Hitachi Digital Services announce 5-year strategic IT partnership
Sign Up For More Events
Sign Up For More Events
News
Preview
9.5
08-01NASDAQ.COMPinnedEnvista (NVST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Preview
9.5
08-01PRnewswirePinnedEnvista Reports Second Quarter 2025 Results
Preview
4.0
08-01BenzingaPiper Sandler Maintains Neutral on Envista Holdings, Raises Price Target to $19
Sign Up For More News
People Also Watch
FAQ
What is Envista Holdings Corp (NVST) stock price today?
What is Envista Holdings Corp (NVST)'s business?
What is the price predicton of NVST Stock?
What is Envista Holdings Corp (NVST)'s revenue for the last quarter?
What is Envista Holdings Corp (NVST)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Envista Holdings Corp (NVST)'s fundamentals?
How many employees does Envista Holdings Corp (NVST). have?